한국지질동맥경화학회 학술대회

The session "Comprehensive Cardiovascular Prevention: CAC and Beyond," joint symposium by the American Society of Preventive Cardiology (ASPC) and the Korean Society of Lipid and Atherosclerosis (KSoLA), will explore the crucial role of Coronary Artery Calcium (CAC) in the prevention of Atherosclerotic Cardiovascular Disease (ASCVD), its clinical implications, and the role of imaging in cardiovascular prevention. Professor Khurram Nasir from Houston Methodist DeBakey Heart & Vascular Center will discuss the role of CAC scoring in the prevention of ASCVD. Professor Jang­Hoon Lee from Kyungpook National University will cover the clinical implications and limitations of CAC scoring. Additionally, Professor Sang-Eun Lee from Ewha Womans University will present on the role of imaging in cardiovascular prevention.

Premature atherosclerosis, marked by the early onset of atherosclerotic cardiovascular disease (ASCVD), is a growing global concern. Understanding its risk factors is essential for developing effective prevention and treatment strategies. This joint session will explore the background, risk factors, and latest research findings on premature atherosclerosis across different regions. Professor Ashraf Reda from Menoufia University (current President of the Egyptian Association of Vascular Biology and Atherosclerosis) will present findings from Egyptian data, providing insights into the prevalence and characteristics of premature atherosclerosis in this region. Professor EL Sayed Farag from Zagazig University will discuss archived case scenarios, highlighting unique cases and outcomes that shed light on the clinical manifestations and progression of this condition. Professor Su-Yeon Choi from Seoul National University will examine metabolic risk factors and their association with ASCVD in young Korean adults, offering a comparative perspective and potential preventive strategies.

New treatments for traditional lipid markers associated with atherosclerosis, as well as for newly emerging lipid markers, are being developed. This session is designed to introduce these new treatments in the field of dyslipidemia. First, Professor Yu-Mi Kang and Professor Andre Zimerman from the Moinhos de Vento Hospital and College of Health Sciences, Brazil will present on clinical research of new agents targeting Lp(a) and TG. Additionally, Professor Kyung-Woo Park from Seoul National University College of Medicine will discuss the current status of the development of next-generation PCSK9 inhibitors. This session is expected to be very helpful in understanding the latest trends in the treatment of dyslipidemia.

This session, titled "Recent advances in metaflammation and atherosclerosis research," will introduce the latest researches in metaflammation and atherosclerosis. Professor Takehiko Yokomizo from Juntendo University will present protective roles of BLT2 receptor on the plasma membrane disruption-induced epithelial cell damage. Professor Mahmoud Abdellatif from the University of Graz will present on the cardioprotective mechanisms of the SGLT2 inhibitor, empagliflozin in myocardial infarction. Professor Yun-Hee Lee from the College of Pharmacy at Seoul National University will discuss TM4SF19-mediated lysosomal activity of macrophages in metaflammation, providing insights into macrophage function in metabolic inflammation. This session promises to offer valuable knowledge on the latest research trends and their practical applications in the field.

This session is a joint session by Latin America and the Korean Society of Lipid and Atherosclerosis (KSoLA), and will address various genetic and environmental factors related to cardiovascular diseases. Professor Hokyou Lee from Yonsei University will discuss atherosclerotic cardiovascular disease and its risk factors in cancer patients. Professor Rodrigo Alonso from Center for Advanced Metabolic Medicine and Nutrition will present research on familial Hypercholesterolemia conducted in the Latam region. Professor Pablo Corral from FASTA University will cover past and current research on Lipoprotein(a), as well as future research directions. Finally, Professor Alvaro Avezum from Sao Paulo University will deliver a lecture on dietary interventions in cardiovascular diseases.

In this special lecture, Professor Jae-Taek Kim, the board of directors of the Korean Society of Lipid and Atherosclerosis and a distinguished professor at Chung-Ang University College of Medicine, will present the culmination of his decades-long research. He will offer an in-depth lecture on the influence of Insulin-like Growth Factor (IGF)-1 signaling pathways on key characteristics of heart disease, including myocardial hypertrophy, cell death, aging, fibrosis, and electrical remodeling. This promises to be a highly insightful and enriching experience, shedding light on critical aspects of cardiovascular health.

This session, titled "New therapeutic strategies for metabolic diseases," will explore the latest treatment strategies and research findings for metabolic diseases. Professor Véronique A. Lacombe from Oklahoma State University will present on "Cardiac-specific SERCA overexpression improves cardiac and systemic glucose metabolism during diabetes: novel therapeutic targets," highlighting innovative therapeutic targets to improve glucose metabolism. Professor Won Kim from Seoul National University will present “ADAMTS4 elicits myeloid-derived immune cell recruitment and liver fibrogenesis in metabolic dysfunction-associated steatotic liver disease,” providing the therapeutic potential of ADAMTS4 in hepatic fibrosis. Professor Il Minn from University of Texas Southwestern Medical Center will discuss "Cardiovascular toxicity induced by radiation therapy and introduction of radiopharmaceutical therapy," shedding light on the cardiovascular side effects of radiation therapy and the potential of radiopharmaceutical therapy. This session promises to provide valuable insights into the latest trends and novel approaches in the treatment of metabolic diseases.

This session will focus on comprehensive cardiac rehabilitation for patients with atherosclerotic cardiovascular disease. We will cover the effectiveness and safety of exercise therapy, dietary control, and cardiac rehabilitation programs for secondary prevention in patients with myocardial infarction, angina, stroke, and peripheral arterial disease. Beyond general exercise and dietary recommendations, Professor Ick-Mo Chung from Ewha Womans University (current President of the Korean Society of Lipid and Atherosclerosis) will discuss the significance and necessity of cardiac rehabilitation, Professor Randal J. Thomas from Mayo Clinic will present the latest insights and applications of cardiac rehabilitation program, Professor Qi Sun from Harvard Medical School will cover nutritional management strategies for cardiometabolic diseases, and Professor Kyuwan Lee from Ewha Womans University will share key insights on exercise therapy for patients with diabetes and cardiovascular disease.

MASLD, type 2 diabetes, and ASCVD are closely related and share etiology in part. MASLD and type 2 diabetes have a common underlying pathophysiology, insulin resistance, and both MASLD and type 2 diabetes are clear risk factors for ASCVD. In this session, we will have an in-depth discussion about how MASLD and type 2 diabetes are related (Professor Kyung-Soo Kim from CHA University), whether MASLD itself is an independent risk factor for ASCVD (Professor Brouwers from Maastricht University), and whether treatment of MASLD can reduce cardiovascular risk (Professor Jae Seung Lee from Yonsei University).

This session is a joint session of the Oman Society of Lipid and Atherosclerosis (OSLA) and the Korean Society of Lipid and Atherosclerosis (KSoLA) and will be held under the theme "Addressing Unmet Needs Among High-Risk Patients With Atherosclerotic Cardiovascular Disease With Novel Lipid-Lowering Therapies". The session will feature in-depth presentations and discussions on the need for novel lipid-lowering therapies in high-risk patients, with speakers from Oman and Korea. In particular, the President and Vice President of OSLA will present the latest findings on residual risk in diabetic patients and unmet needs in familial hypercholesterolemia in Oman and the Middle East. This session aims to provide insight into the current status and characteristics of lipid atherosclerosis in Korea and Oman. Despite being located in the same region of Asia, these two countries differ significantly in terms of geography, society, and culture. This discussion will be highly valuable for the exchange of knowledge on lipid atherosclerosis between Korea and Oman.

Lipoprotein(a) is a significant genetic risk factor for cardiovascular diseases, and guidelines recommend it be measured at least once in a lifetime for all adults to assess individual cardiovascular risk. Professor Børge Nordestgaard from the University of Copenhagen will deliver a lecture in this session. Professor Nordestgaard has played a pivotal role in the recognition of lipoprotein(a) as a risk factor for cardiovascular disease, aortic valve calcification, and stenosis through his extensive research on biochemical and genetic biomarkers. His work has significantly contributed to guidelines for managing dyslipidemias, including lipoprotein(a), triglycerides, and familial hypercholesterolemia. This session will provide an overview of key findings from observational and genetic studies on lipoprotein(a) in the context of cardiovascular disease, discuss clinical applications, and explore novel therapeutic targets involving lipoprotein(a).

This session is a joint symposium organized by the Australian Atherosclerosis Society (MS) and the Korean Society of Lipid and Atherosclerosis (KSoLA), focusing on vascular abnormalities related to diabetes. The session will feature presentations by three distinguished professors on different topics. First, Professor Judy de Haan from the Baker Heart and Diabetes Institute in Australia will give a lecture on "Targeting Inflammation to lessen diabetes-associated cardiovascular complications." This presentation will cover strategies for controlling inflammation to improve cardiovascular health in diabetic patients. The second speaker is Professor Jae-Han Jeon from Kyungpook National University in Korea, who will present on "Diabetic Nephropathy and Endothelial Dysfunction." This presentation will delve into the kidney diseases caused by diabetes and the changes in endothelial cell function associated with it. Lastly, Professor Georges Grau from the University of Sydney in Australia will present an intriguing case study on "Vascular dysfunction in cerebral malaria: a peculiar case of immuno-thrombosis, underpinned by extracellular vesicles," focusing on immunopathology related to extracellular vesicles. This presentation will explore vascular changes in the brain during malaria infection, discussing the related immune responses and pathological mechanisms. We hope this session will provide an opportunity to explore and discuss various vascular abnormalities in diabetes.

This session will present the latest research on dietary factors influencing cardiometabolic health. Professor Jung Eun Kim from the National University of Singapore will discuss the impact of consuming foods rich in carotenoids on promoting healthy dietary patterns and cardiovascular protection. Following this, Professor Bohkyung Kim from Pusan National University will introduce the latest findings from experiments on dietary interventions to improve cardiometabolic health, providing insights into current perspectives. Lastly, Professor Qi Sun from Harvard University will comprehensively illuminate the effects of plant-based diets on cardiometabolic health and engage in profound discussions on related topics. This session will explore the significant role of dietary choices in cardiovascular health through diverse research outcomes, offering valuable research insights to participants.

This session will be a joint endeavor between the Malaysian Society of Atherosclerosis and the Korean Society of Lipid and Atherosclerosis (KSoLA), focusing on the metabolic aspects of atherosclerosis. The first speaker, Professor Yoon Kyung Cho from University of Ulsan, will present the latest research on the relationship between metabolites, organ crosstalk, and atherosclerosis. The second speaker, Professor Kyung Mook Choi from Korea University, will discuss the impact of various organokines on atherosclerosis. Lastly, Professor Lim Lee-Ling from University Malaya Medical Centre will address the topics of metabolic-associated fatty liver disease, obesity, and atherosclerosis. Given the recent epidemiological findings that highlight diabetes, obesity, and metabolic-associated fatty liver disease as major contributors to atherosclerosis, we anticipate that this session will be highly beneficial for all attendees.

The joint symposium with the Japan Atherosclerosis Society (JAS) will explore cutting-edge advancements in incretin-based multi-agonist therapies for cardiometabolic disorders. Three distinguished speakers will share their expertise on this crucial topic. Professor Yasuo Terauchi from Yokohama City University, Japan, will discuss the efficacy and safety of tirzepatide, a GIP and GLP-1 dual agonist, in type 2 diabetes. Professor Chang Hee Jung from the University of Ulsan, Republic of Korea, will delve into the implications of GLP-1/GIP therapies for atherosclerotic cardiovascular disease (ASCVD). Professor Yong-ho Lee from Yonsei University, Republic of Korea, will elucidate the potential mechanisms underlying GLP-1/GIP therapies. This session promises to provide a comprehensive overview of the latest developments in multi-agonist therapies, their clinical applications, and their potential to revolutionize cardiometabolic disease treatment.

Recently, there has been a surge in efforts to find solutions to metabolic disease treatment strategies from adipose tissue biology, such as systematically establishing the hallmarks of adipose tissue dysfunction in the development of metabolic diseases. This session will focus on the latest research on the biological functions of adipose tissue and adipocytes, conducted from various perspectives. Professor Jae Myoung Suh from KAIST will present a study on new regulatory mechanisms of fuel metabolism in adipose tissue from RNA biology perspective. Professor Motoharu Awazawa from National Center for Global Health and Medicine (NCGM) will discuss the effects of new antidiabetic drugs on system-level metabolic physiology including adipose tissues. Professor Kae Won Cho from Soonchunhyang University (SIMS) will discuss the new pathophysiological roles of adipose dendritic cells in metabolic diseases.

Among the pathophysiological aspects of atherosclerosis, a traditionally overlooked factor is the biomechanical factors such as shear stress. This session aims to address these biomechanical factors. The first speaker, Professor Chang-Hoon Woo from Yeungnam University, will summarize the molecular biological mechanisms of how shear stress on endothelial cells is related to atherosclerosis. The second speaker, Professor Hanjoong Jo from Emory University, will present his recent achievements on flow-mediated reprogramming in endothelial cells. Finally, Professor Kwan Yong Lee from the Department of Cardiology at the Catholic University of Korea will introduce his research on how atherosclerosis progresses rapidly and develops into a disease through plaque and hemodynamic analysis in patients. This session is expected to help us understand and recognize the importance of the impact of biomechanical factors on atherosclerosis, which has been overlooked until now.

Dr. R. Scott Wright is a Professor of Medicine and a consultant in cardiology at the Mayo Clinic in Rochester. Dr. Wright focuses his research on acute coronary syndrome, dyslipidemia, type 2 diabetes, and valvular heart disease. He is a renowned international leader and an active clinical investigator of PRINCESS, CRISP and ORION programs. At ICoLA 2024, he will deliver a keynote lecture entitled, “Recent advances in the treatment of dyslipidemia with PCSK9 therapy and a look into potential new options in the next 10 years”.

In this special lecture, Professor Sung Nim Han from Seoul National University will deliver a lecture on the topic "Dissecting dietary approaches targeting lipid biomarkers." Professor Han, former president of the Korean Nutrition Society and the Korean Society of Clinical Nutrition, will systematically explore the impact of various dietary factors on lipid biomarkers. The lecture will include in-depth discussions on how dietary management affects lipid biomarkers in the bloodstream, contributing to a deeper understanding of its positive and negative impacts on health. Moreover, Professor Han will share insights based on extensive research experience and discuss future clinical application potential and vision.

The joint symposium with the Taiwan Society of Lipids & Atherosclerosis (TSLA) will delve into the pivotal role of remnant cholesterol in the statin era. We will explore its impact on cardiometabolic health, cardiovascular disease, and treatment options, with a focus on Asian populations. Professor Jun Hwa Hong from Eulji University will begin with "How does remnant cholesterol related to cardiometabolic multimorbidity" highlighting the links between remnant cholesterol and various cardiometabolic conditions. Next, Dr. Donna Shu-Han Lin from Shin Kong Wu Ho­Su Memorial Hospital will present "Epidemiologic evidence of hypertriglyceridemia or remnant cholesterol on cardiovascular disease" providing key epidemiological insights. Finally, Professor Youngwoo Jang from Gachon University will discuss "Treatments targeting remnant cholesterol or hypertriglyceridemia in Asians: do we have an option?" offering a detailed analysis of therapeutic strategies for Asian patients. Join us to gain a comprehensive understanding of remnant cholesterol in contemporary cardiovascular care.

This joint session is organized for academic exchange between the Korean Society of Lipid and Atherosclerosis (KSoLA) and the Society for Heart and Vascular Metabolism (SHVM). The first speaker, Professor Tae-Sik Park from Gachon University, will present on the role and regulatory mechanisms of S1P, a bioactive Iipid mediator and a sphingolipid metabolite, in NASH, based on his years of research. The second speaker, Professor Linda Peterson from Washington University, will discuss her research achievements on the role of ceramide, another sphingolipid metabolite, in cardiovascular diseases. The final speaker, Professor Helen E. Collins from the University of Louisville, will address the mechanisms of cardiac changes during pregnancy, a somewhat different topic. We hope that this session will help in understanding new risk factors and mechanisms in various diseases and physiological changes.

Atherosclerosis is a well-known inflammatory cardiovascular disease involving various immune cells. This session aims to discuss the latest research on the role of innate immune cells, which are crucial in the progression of atherosclerosis. Professor Andreas Zirlik from Medical University of Graz will present the latest insights on innate immune markers related to cardiovascular diseases. Professor Yeonseok Chung from Seoul National University will share his recent findings on the lipid metabolism­ related inflammatory mechanisms of dendritic cells, one of the key innate immune cells. Professor Christoph J. Binder from Medical University of Vienna will discuss the role of extracellular vesicles in the pathogenesis of atherothrombosis, and finally, Professor Andrew Murphy from the Baker Heart and Diabetes Institute will present the latest insights on hematopoiesis-related pathogenesis in atherosclerosis.

This session will discuss novel therapeutic targets in atherosclerosis. The first lecture will introduce gene editing technology for treating dyslipidemia and atherosclerosis, presented by Professor Giuseppe Danilo Norata from the University of Milan. Following this, Professor Jin Won Kim from Korea University will present targeted treatment strategies for atherosclerotic plaque using intravascular imaging. Lastly, Professor Alberico L. Catapano from the University of Milan and IRCCS Multimedica will deliver a lecture about the LDL burden for cardiovascular prevention. This session aims to present the latest research and innovative therapeutic approaches for patients with atherosclerosis.